RestenASE

Drug Profile

RestenASE

Alternative Names: Anti-proliferating cell nuclear antigen oligonucleotide

Latest Information Update: 28 Sep 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immusol
  • Developer Cedars-Sinai Health System
  • Class Ribozymes
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 28 Sep 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 18 Feb 1999 Preclinical data have been added to the pharmacodynamics section
  • 29 Oct 1998 Preclinical development for Coronary artery restenosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top